Patents by Inventor Timothy David Jones
Timothy David Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
Publication number: 20170129945Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.Type: ApplicationFiled: May 28, 2014Publication date: May 11, 2017Inventors: Richard A. FISHER, Robert George Edward HOLGATE, Francis Joseph CARR, Timothy David JONES -
Patent number: 9605081Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: GrantFiled: March 30, 2016Date of Patent: March 28, 2017Assignee: CELLDEX THERAPEUTICS, INC.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 9603911Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.Type: GrantFiled: March 3, 2014Date of Patent: March 28, 2017Assignee: RESEARCH CORPORATION TECHNOLOGIES, INC.Inventors: Kurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn
-
Publication number: 20170044270Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: ApplicationFiled: April 27, 2015Publication date: February 16, 2017Applicant: CCAM BIOTHERAPEUTICS LTD.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
-
Publication number: 20170037386Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.Type: ApplicationFiled: August 11, 2016Publication date: February 9, 2017Applicant: Intrexon CorporationInventors: Timothy David Jones, Francis Joseph Carr
-
Publication number: 20160311924Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: ApplicationFiled: March 30, 2016Publication date: October 27, 2016Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 9447387Abstract: Pseudomonas exotoxin A or “PE” is a 66kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.Type: GrantFiled: December 30, 2015Date of Patent: September 20, 2016Assignee: INTREXON CORPORATIONInventors: Timothy David Jones, Francis Joseph Carr
-
Patent number: 9371517Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.Type: GrantFiled: December 5, 2014Date of Patent: June 21, 2016Assignee: INTREXON CORPORATIONInventors: Timothy David Jones, Francis Joseph Carr
-
Publication number: 20160129133Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.Type: ApplicationFiled: June 23, 2014Publication date: May 12, 2016Applicant: Nexlmmune, Inc.Inventors: Bruce McCreedy, Timothy David Jones, Francis Joseph Carr
-
Patent number: 9334332Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: GrantFiled: July 24, 2013Date of Patent: May 10, 2016Assignee: KOLLTAN PHARMACEUTICALS, INC.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
Publication number: 20160115223Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.Type: ApplicationFiled: May 28, 2014Publication date: April 28, 2016Inventors: Richard A. FISHER, Robert George, Edward HOLGATE, Francls Joseph CARR, Timothy David JONES -
Patent number: 9321841Abstract: The present invention relates to novel humanised antibodies against human CD52 and their use in methods of treating or preventing human diseases.Type: GrantFiled: June 1, 2012Date of Patent: April 26, 2016Assignee: ANTITOPE LIMITEDInventors: Timothy David Jones, Robert George Edward Holgate, Francis Joseph Carr
-
Publication number: 20160106819Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.Type: ApplicationFiled: March 3, 2014Publication date: April 21, 2016Inventors: Kurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn
-
Publication number: 20160108377Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.Type: ApplicationFiled: December 30, 2015Publication date: April 21, 2016Applicant: Intrexon CorporationInventors: Timothy David Jones, Francis Joseph Carr
-
Publication number: 20160031992Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent ?v?6-mediated diseases such as fibrosis and cancer.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Inventors: Shelia M. Violette, Paul H. Weinreb, Timothy David Jones, Francis Joseph Carr, Anja Sibylle Tessarz
-
Publication number: 20160017025Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.Type: ApplicationFiled: March 13, 2014Publication date: January 21, 2016Inventors: Sarit SAMIRA, Nurit RACHAMIM, Michael TAL, Ronald ELLIS, Idan RAKOVER, Rom E. ELIAZ, Beka SOLOMON, Timothy David JONES, Francis Joseph CARR, Polina RABINOVICH-TOIDMAN, Meital SOOLIMAN
-
Publication number: 20160017042Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent ?v?6-mediated diseases such as acute tissue injury, fibrosis, and cancer.Type: ApplicationFiled: March 14, 2014Publication date: January 21, 2016Inventors: Shelia M. Violette, Paul H. Weinreb, Timothy David Jones, Francis Joseph Carr, Anja Sibylle Tessarz
-
Publication number: 20150291941Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.Type: ApplicationFiled: December 5, 2014Publication date: October 15, 2015Applicant: INTREXON CORPORATIONInventors: Timothy David Jones, Francis Joseph Carr
-
Publication number: 20150175699Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.Type: ApplicationFiled: March 12, 2013Publication date: June 25, 2015Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
-
Publication number: 20150125878Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.Type: ApplicationFiled: April 24, 2013Publication date: May 7, 2015Inventors: Daniel Clive Anthony, Sandra Jane Campbell, Francis Joseph Carr, Robin Patrick Choudhury, Benjamin Guy Davis, Timothy David Jones, Nicola Ruth Sibson